mikehav

http://www.etfinnovators.com
Total Rating:
0 / 0

51 Comments

    • Tue Jul 22nd 09:35 AM | Rating: 0 0
      Commented on:
      NationCapShares: An ETF Idea for Developed, Emerging and Frontier Markets
      thanks for your interest - the ETF licensing deals and trademarks are already underway
      View article »
    • Thu Jul 17th 05:41 AM | Rating: 0 0
      Commented on:
      Is Tobacco a Safe Haven in the Current Market?
      Lorillard (LO) is #13 on the spreadsheet w/ a 3% weight in the 23-stock index with data included since its spin-off at the end of June.
      View article »
    • Wed Jul 16th 05:30 AM | Rating: 0 0
      Commented on:
      A Fat Yield at Pfizer
      Sorry, the link above didn't work - Just Google "third class drugs" for more inffo on the topic
      View article »
    • Wed Jul 16th 05:27 AM | Rating: 0 0
      Commented on:
      A Fat Yield at Pfizer
      Could also lobby FDA make the statin drgus such as Lipitor available in low doses as a new "3rd Class of Drugs" available only after consultation with a pharmacist. Already sell Plan B emergency contraceptive and pseudoephedrine-contai... products behind-the-counter only. Prilosec OTC is a very good example of successful switch to OTC for a former Rx-only brand drug that would otherwise have very low sales now due to generics.

      Check out this article for an overview:

      www.medscape.com/viewa...
      View article »
    • Sun Jul 13th 13:16 PM | Rating: 0 0
      Commented on:
      A Bullish Prognosis for Global Healthcare ETFs
      Looks like HQL would appeal to investors looking for higher risk/reward investments in the healthcare sector. Has about 60% invested in biopharma, med devices & diagnostics. Of the top holdings Biomarin (BMRN) has done very well while Acadia Pharma (ACAD) is the worst performer. The fund trades at 15% discount to its NAV with a 9.4% distribution rate. See the full profile at www.etfconnect.com/sel...
      View article »
    • Sun Jul 13th 13:00 PM | Rating: 0 0
      Commented on:
      A Bullish Prognosis for Global Healthcare ETFs
      I think the long-overdue rotation into healthcare is starting to occur and would favor RXL going forward. The top holdings are JNJ (11%), PFE (8%), MRK (5%), and ABT (4.7%) which should fare well with above-average dividend yields and products that people use regardless of the overall economy. JNJ is actually close to its 52-week high while ABT is mid-range and MRK/PFE are close to their lows. The more it appears a prolonged recession is likely; the better these stocks and RXL should perform.
      View article »
    • Sun Jul 6th 14:29 PM | Rating: 0 0
      Commented on:
      A New Strategy for EXACT Sciences
      Many blue chip and former large-caps are down huge amounts over the last year as well & the bear market has been especially tough for small/micro cap biotech stocks.

      I have also written about stocks on the Motley Fool & other sites such as Sequenom (SQNM), Isis Pharma (ISIS), Alnylam (ALNY), Xenoport (XNPT), Vivus (VVUS), VisICU (EICU), North Pitt (NPSI), Savient Pharma (SVNT), Allos Therapeutics (ALTH) that have done much better than the examples you list. Sequenom alone is almost four-fold from last year.
      View article »
    • Mon Jan 28th 20:51 PM | Rating: 0 0
      Commented on:
      The Right Price for Rite Aid
      then why are you are reading it & why don't you write something better without the caps lock ON!
      View article »
    • Fri Jan 25th 14:03 PM | Rating: 0 0
      Commented on:
      My Recession-Proof ETF
      I am still in the process of obtaining a partner to bring this ETF and my other proposals to the market as the process requires a lot of money and regulatory filings with the SEC.
      View article »
    • Fri Jan 25th 09:50 AM | Rating: 0 0
      Commented on:
      Innovative Investments in Animal Healthcare
      Pfizer recently reported animal health sales for 2007 of $2.6 billion or just over 5% of total revenue of $48.6 billion
      View article »
    • Sun Jan 20th 10:29 AM | Rating: 0 0
      Commented on:
      The Return of Tobacco: Safe Haven in a Volatile Market
      Please contact me via email (mike@mikehav.com) if you are interested in viewing the details & possibly commercializing my idea for a Global Tobacco ETF/index.
      View article »
    • Fri Jan 18th 10:33 AM | Rating: 0 0
      Commented on:
      The Right Price for Rite Aid
      Well said!
      View article »
    • Thu Jan 10th 15:19 PM | Rating: 0 0
      Commented on:
      The Right Price for Rite Aid
      Now trading at $2.20 - Let's give it until the end of 2008 and see who is right on this one - Coutu Group is content to view this as a long-term story despite huge losses since B/E deal on the RAD they received.
      View article »
    • Thu Jan 10th 10:22 AM | Rating: 0 0
      Commented on:
      The Right Price for Rite Aid
      That's why its trading at/below $2/share - much better risk/reward at these levels for investors since the stock is priced like a call option with no expiration date as long as RAD stays in business, which I believe it will.
      View article »
    • Tue Dec 25th 09:12 AM | Rating: 0 0
      Commented on:
      5 Emerging Healthcare Stock Picks for 2008
      All of my picks should be regarded as speculative, as they are micro/small-cap stocks from the healthcare sector with market caps below $500 million. OSUR is included because it could have an OTC version of its oral HIV test on the market bythis time next year, in addition to the oral HCV test for use by HC professionals. These are all high-risk, high-reward stocks.
      View article »
Loading...
Symbols:
Authors:
Quick Links:
Contribute an Article Become a Seeking Alpha Contributor

Transcripts

More Transcripts»